Physician profile
Shrish Calla
NPI 1497976526
$3,257.02
in general payments reported to CMS, 2019-2025
21 companies · $90.00 in 2025
The $90.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $480 · 2021: $543 · 2022: $566 · 2023: $610 · 2024: $518 · 2025: $90.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.79 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.26 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $402.47 | 2019-2024 | Breztri, Farxiga |
| Abbvie INC. | $335.02 | 2021-2024 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $263.29 | 2019-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $182.43 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $170.43 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $170.14 | 2023-2024 | Veozah, Myrbetriq |
| Amgen INC. | $157.11 | 2019-2024 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $145.81 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $115.14 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.14 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $107.90 | 2019-2021 | |
| Pfizer INC. | $93.14 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $91.25 | 2019-2022 | |
| Dexcom, INC. | $90.00 | 2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $76.89 | 2022-2024 | |
| Esperion Therapeutics, INC. | $64.94 | 2021-2023 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $55.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $46.04 | 2020-2021 | |
| Exact Sciences Corporation | $36.54 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shrish Calla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.